Core Viewpoint - The company is focusing on clinical needs and steadily expanding its research pipeline in key areas such as oncology, antiviral treatments, and ophthalmology, with a commitment to enhancing innovation in drug development [1] Group 1: Drug Development Progress - The company has 15 projects progressing steadily in its innovation pipeline [1] - The modified new drug Panxin®-Mercaptopurine Tablets (Ⅱ) has been approved for production, filling a gap in precision treatment for childhood leukemia in China, achieving a balance between safety and efficacy [1] - The first-class anti-tumor drug DC50292A has received clinical approval from both the National Medical Products Administration and the FDA [1] - The first-class anti-tumor new drug DC05F01 is continuing to enroll participants for its Phase II clinical trial [1] - The 1.1 class biological drug J002 for treating dry eye syndrome has obtained clinical implied approval [1] Group 2: Future Directions - The company plans to accelerate its layout in major diseases, small molecule innovative drugs, and small nucleic acid drugs [1] - There is a continuous emphasis on strengthening independent innovation and cutting-edge technology reserves [1] - The company aims to comprehensively speed up its research and development transformation process [1]

Core Viewpoint - The company plans to distribute a cash dividend of 1.00 yuan per 10 shares for the first half of 2025, which represents 10.65% of the net profit attributable to shareholders [2][53]. Group 1: Profit Distribution Plan - The total number of shares after the cancellation of restricted stocks is 1,038,757,509, leading to a total cash dividend distribution of approximately 103.88 million yuan (including tax) [2][53]. - The remaining undistributed profits amount to approximately 5.90 billion yuan for the parent company and 9.73 billion yuan for the consolidated entity, which will be carried forward for future distribution [2]. - The profit distribution plan is subject to approval by the shareholders' meeting [3][55]. Group 2: Company Bond Issuance - The company plans to issue bonds with a total scale not exceeding 30 billion yuan, with specific issuance amounts to be determined based on market conditions and funding needs [17][60]. - The bonds will have a face value of 100 yuan each and will be issued at par [61]. - The funds raised will be used for repaying interest-bearing debts, supporting investments and acquisitions, and supplementing working capital [67][77]. Group 3: Company Overview and Financial Data - The company has a total share capital of 1,038,836,522 shares as of June 30, 2025 [2]. - The company’s financial condition is stable, with a good credit rating over the past three years [71]. - The company has been focusing on enhancing operational quality and increasing investment returns through various initiatives [78].